NDC 66215-718

UPTRAVI

Selexipag

UPTRAVI is a Intravenous Injection, Powder, For Solution in the Human Prescription Drug category. It is labeled and distributed by Actelion Pharmaceuticals Us, Inc.. The primary component is Selexipag.

• Product ID: 66215-718_528f1900-3262-4007-9d1b-a8eb7034b5e1
• NDC: 66215-718
• Product Type: Human Prescription Drug
• Proprietary Name: UPTRAVI
• Generic Name: Selexipag
• Dosage Form: Injection, Powder, For Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2021-07-29
• Marketing Category: NDA /
• Application Number: NDA214275
• Labeler Name: Actelion Pharmaceuticals US, Inc.
• Substance Name: SELEXIPAG
• Active Ingredient Strength: 1800 ug/10mL
• Pharm Classes: Prostacyclin Receptor Agonist [EPC],Prostacyclin Receptor Agonists [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 66215-718-01

1 VIAL, SINGLE-DOSE in 1 CARTON (66215-718-01) > 10 mL in 1 VIAL, SINGLE-DOSE

• Marketing Start Date: 2021-07-29
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "UPTRAVI" or generic name "Selexipag"

NDC	Brand Name	Generic Name
66215-602	UPTRAVI	Selexipag
66215-604	UPTRAVI	Selexipag
66215-606	UPTRAVI	Selexipag
66215-608	UPTRAVI	Selexipag
66215-610	UPTRAVI	Selexipag
66215-612	UPTRAVI	UPTRAVI
66215-614	UPTRAVI	UPTRAVI
66215-616	UPTRAVI	UPTRAVI